A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
Latest Information Update: 19 Dec 2019
Price :
$35 *
At a glance
- Drugs Felcisetrag (Primary)
- Indications Alzheimer's disease; Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Theravance
- 01 Sep 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2012 New trial record